Likewise, Esawy et al. and Aslan et al. observed significant declines in serum irisin levels among 150 bladder cancer [63] and 80 prostate cancer patients [64], respectively, further supporting a potential tumour-suppressive role for irisin (Table 2 and Table 3). Here, FNDC5 is linked to prostate carcinoma.